Although the use of epidrugs in cancer is still in its early stages, several anticancer therapeutic drugs targeting epigenetic modifiers, such as DNMT, EZH2 and HDAC, have been approved by the FDA and used in clinics; additional epigenetic drugs targeting chromatin modifiers are currently under clinical trial investigation (for review [27]). This evidence concerns the gene HDAC9 and cancer.